MX2023010297A - Metodos para tratar el sindrome de quilomicronemia familiar. - Google Patents
Metodos para tratar el sindrome de quilomicronemia familiar.Info
- Publication number
- MX2023010297A MX2023010297A MX2023010297A MX2023010297A MX2023010297A MX 2023010297 A MX2023010297 A MX 2023010297A MX 2023010297 A MX2023010297 A MX 2023010297A MX 2023010297 A MX2023010297 A MX 2023010297A MX 2023010297 A MX2023010297 A MX 2023010297A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- chylomicronemia syndrome
- familial chylomicronemia
- treating familial
- treating
- Prior art date
Links
- 208000016667 Familial chylomicronemia syndrome Diseases 0.000 title abstract 3
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 abstract 1
- 229960003566 lomitapide Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155960P | 2021-03-03 | 2021-03-03 | |
| US202163165457P | 2021-03-24 | 2021-03-24 | |
| PCT/US2022/018672 WO2022187463A1 (en) | 2021-03-03 | 2022-03-03 | Methods for treating familial chylomicronemia syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010297A true MX2023010297A (es) | 2023-09-12 |
Family
ID=80819670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010297A MX2023010297A (es) | 2021-03-03 | 2022-03-03 | Metodos para tratar el sindrome de quilomicronemia familiar. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240165093A1 (https=) |
| EP (1) | EP4301361A1 (https=) |
| JP (1) | JP2024508334A (https=) |
| KR (1) | KR20230153375A (https=) |
| AU (1) | AU2022231007A1 (https=) |
| BR (1) | BR112023016943A2 (https=) |
| CA (1) | CA3208189A1 (https=) |
| IL (1) | IL305191A (https=) |
| MX (1) | MX2023010297A (https=) |
| WO (1) | WO2022187463A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186856A1 (en) | 2020-07-29 | 2022-02-03 | Ruth NALLEN | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| KR101494067B1 (ko) | 2004-03-05 | 2015-02-16 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법 |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
-
2022
- 2022-03-03 CA CA3208189A patent/CA3208189A1/en active Pending
- 2022-03-03 AU AU2022231007A patent/AU2022231007A1/en active Pending
- 2022-03-03 MX MX2023010297A patent/MX2023010297A/es unknown
- 2022-03-03 BR BR112023016943A patent/BR112023016943A2/pt unknown
- 2022-03-03 JP JP2023553354A patent/JP2024508334A/ja active Pending
- 2022-03-03 IL IL305191A patent/IL305191A/en unknown
- 2022-03-03 EP EP22711788.4A patent/EP4301361A1/en active Pending
- 2022-03-03 US US18/548,798 patent/US20240165093A1/en active Pending
- 2022-03-03 WO PCT/US2022/018672 patent/WO2022187463A1/en not_active Ceased
- 2022-03-03 KR KR1020237028890A patent/KR20230153375A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL305191A (en) | 2023-10-01 |
| BR112023016943A2 (pt) | 2023-10-31 |
| US20240165093A1 (en) | 2024-05-23 |
| AU2022231007A9 (en) | 2024-09-19 |
| AU2022231007A1 (en) | 2023-08-17 |
| KR20230153375A (ko) | 2023-11-06 |
| CA3208189A1 (en) | 2022-09-09 |
| JP2024508334A (ja) | 2024-02-26 |
| EP4301361A1 (en) | 2024-01-10 |
| WO2022187463A1 (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018271990A1 (en) | Covalent inhibitors of KRAS | |
| MX2022001421A (es) | Compuesto tetracíclico, método de preparación y uso del mismo. | |
| ZA202208783B (en) | Kras mutant protein inhibitors | |
| MX2025002170A (es) | Inhibidores de kras g12c | |
| PH12022550681A1 (en) | Fused pyridone compound, and preparation method therefor and use thereof | |
| PH12020550256A1 (en) | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
| MX388781B (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c. | |
| MX2022004983A (es) | Composiciones de profarmaco y metodos de tratamiento. | |
| MX2022005335A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| MX2021010870A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2024015576A (es) | Tratamiento para migra?as | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| PH12021550883A1 (en) | Crystalline salts of a plasma kallikrein inhibitor | |
| MX2023010297A (es) | Metodos para tratar el sindrome de quilomicronemia familiar. | |
| MX2023010449A (es) | Composiciones y métodos para tratar la policitemia. | |
| MX2023013148A (es) | Iptacopan para el tratamiento del sindrome uremico hemolitico atipico. | |
| MX2024010644A (es) | Uso de iptacopan para el tratamiento de la nefritis lupica. | |
| EP4474014A3 (en) | Non-immunosuppressive fk506 analogs and use thereof | |
| PH12021552499A1 (en) | Methods for the treatment of beta-thalassemia | |
| MX2025004545A (es) | 3,4 a, 5, 7, 8, 8a-hexahidro-4h-tiopirano [4,3-d] pirimidin-4-onas 2-sustituidas para el tratamiento de heridas | |
| CR20250232A (es) | Composición farmacéutica para la prevención o tratamiento contra úlcera péptica relacionada de fármacos, que comprende zastaprazán o una sal farcéuticamente aceptable del mismo | |
| HK40103549A (en) | Methods for treating familial chylomicronemia syndrome |